186 related articles for article (PubMed ID: 19002170)
1. MAL promoter hypermethylation as a novel prognostic marker in gastric cancer.
Buffart TE; Overmeer RM; Steenbergen RD; Tijssen M; van Grieken NC; Snijders PJ; Grabsch HI; van de Velde CJ; Carvalho B; Meijer GA
Br J Cancer; 2008 Dec; 99(11):1802-7. PubMed ID: 19002170
[TBL] [Abstract][Full Text] [Related]
2. Hypermethylated MAL gene - a silent marker of early colon tumorigenesis.
Lind GE; Ahlquist T; Kolberg M; Berg M; Eknaes M; Alonso MA; Kallioniemi A; Meling GI; Skotheim RI; Rognum TO; Thiis-Evensen E; Lothe RA
J Transl Med; 2008 Mar; 6():13. PubMed ID: 18346269
[TBL] [Abstract][Full Text] [Related]
3. Repression of MAL tumour suppressor activity by promoter methylation during cervical carcinogenesis.
Overmeer RM; Henken FE; Bierkens M; Wilting SM; Timmerman I; Meijer CJ; Snijders PJ; Steenbergen RD
J Pathol; 2009 Nov; 219(3):327-36. PubMed ID: 19662663
[TBL] [Abstract][Full Text] [Related]
4. T-lymphocyte maturation-associated protein gene as a candidate metastasis suppressor for head and neck squamous cell carcinomas.
Beder LB; Gunduz M; Hotomi M; Fujihara K; Shimada J; Tamura S; Gunduz E; Fukushima K; Yaykasli K; Grenman R; Shimizu K; Yamanaka N
Cancer Sci; 2009 May; 100(5):873-80. PubMed ID: 19445022
[TBL] [Abstract][Full Text] [Related]
5. Inactivation of the MAL gene in breast cancer is a common event that predicts benefit from adjuvant chemotherapy.
Horne HN; Lee PS; Murphy SK; Alonso MA; Olson JA; Marks JR
Mol Cancer Res; 2009 Feb; 7(2):199-209. PubMed ID: 19208741
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic silencing of MAL, a putative tumor suppressor gene, can contribute to human epithelium cell carcinoma.
Cao W; Zhang ZY; Xu Q; Sun Q; Yan M; Zhang J; Zhang P; Han ZG; Chen WT
Mol Cancer; 2010 Nov; 9():296. PubMed ID: 21092172
[TBL] [Abstract][Full Text] [Related]
7. Elevated MAL expression is accompanied by promoter hypomethylation and platinum resistance in epithelial ovarian cancer.
Lee PS; Teaberry VS; Bland AE; Huang Z; Whitaker RS; Baba T; Fujii S; Secord AA; Berchuck A; Murphy SK
Int J Cancer; 2010 Mar; 126(6):1378-89. PubMed ID: 19642140
[TBL] [Abstract][Full Text] [Related]
8. Odd-skipped related 1 is a novel tumour suppressor gene and a potential prognostic biomarker in gastric cancer.
Otani K; Dong Y; Li X; Lu J; Zhang N; Xu L; Go MY; Ng EK; Arakawa T; Chan FK; Sung JJ; Yu J
J Pathol; 2014 Nov; 234(3):302-15. PubMed ID: 24931004
[TBL] [Abstract][Full Text] [Related]
9. MAL and TMEM220 are novel DNA methylation markers in human gastric cancer.
Choi B; Han TS; Min J; Hur K; Lee SM; Lee HJ; Kim YJ; Yang HK
Biomarkers; 2017 Feb; 22(1):35-44. PubMed ID: 27329150
[TBL] [Abstract][Full Text] [Related]
10. Prognostic impact of expression and methylation status of DENN/MADD domain-containing protein 2D in gastric cancer.
Kanda M; Shimizu D; Nomoto S; Takami H; Hibino S; Oya H; Hashimoto R; Suenaga M; Inokawa Y; Kobayashi D; Tanaka C; Yamada S; Fujii T; Nakayama G; Sugimoto H; Koike M; Fujiwara M; Kodera Y
Gastric Cancer; 2015 Apr; 18(2):288-96. PubMed ID: 24695972
[TBL] [Abstract][Full Text] [Related]
11. Pharmacologic unmasking of epigenetically silenced genes in breast cancer.
Ostrow KL; Park HL; Hoque MO; Kim MS; Liu J; Argani P; Westra W; Van Criekinge W; Sidransky D
Clin Cancer Res; 2009 Feb; 15(4):1184-91. PubMed ID: 19228724
[TBL] [Abstract][Full Text] [Related]
12. The value of serum RASSF10 hypermethylation as a diagnostic and prognostic tool for gastric cancer.
Xue WJ; Feng Y; Wang F; Li P; Liu YF; Guo YB; Wang ZW; Mao QS
Tumour Biol; 2016 Aug; 37(8):11249-57. PubMed ID: 26945573
[TBL] [Abstract][Full Text] [Related]
13. Aberrant gene promoter methylation of p16, FHIT, CRBP1, WWOX, and DLC-1 in Epstein-Barr virus-associated gastric carcinomas.
He D; Zhang YW; Zhang NN; Zhou L; Chen JN; Jiang Y; Shao CK
Med Oncol; 2015 Apr; 32(4):92. PubMed ID: 25720522
[TBL] [Abstract][Full Text] [Related]
14. Promoter hypermethylation of multiple genes in early gastric adenocarcinoma and precancerous lesions.
Zou XP; Zhang B; Zhang XQ; Chen M; Cao J; Liu WJ
Hum Pathol; 2009 Nov; 40(11):1534-42. PubMed ID: 19695681
[TBL] [Abstract][Full Text] [Related]
15. Frequent loss of RUNX3 expression by promoter hypermethylation in gastric carcinoma.
Oshimo Y; Oue N; Mitani Y; Nakayama H; Kitadai Y; Yoshida K; Ito Y; Chayama K; Yasui W
Pathobiology; 2004; 71(3):137-43. PubMed ID: 15051926
[TBL] [Abstract][Full Text] [Related]
16. Intragenic DNA methylation concomitant with repression of ATP4B and ATP4A gene expression in gastric cancer is a potential serum biomarker.
Raja UM; Gopal G; Rajkumar T
Asian Pac J Cancer Prev; 2012; 13(11):5563-8. PubMed ID: 23317218
[TBL] [Abstract][Full Text] [Related]
17. Detection of aberrant hypermethylated spastic paraplegia-20 as a potential biomarker and prognostic factor in gastric cancer.
Zhang H; Song Y; Xia P; Cheng Y; Guo Q; Diao D; Wang W; Wu X; Liu D; Dang C
Med Oncol; 2014 Feb; 31(2):830. PubMed ID: 24381142
[TBL] [Abstract][Full Text] [Related]
18. Detection of RASSF1A promoter hypermethylation in serum from gastric and colorectal adenocarcinoma patients.
Wang YC; Yu ZH; Liu C; Xu LZ; Yu W; Lu J; Zhu RM; Li GL; Xia XY; Wei XW; Ji HZ; Lu H; Gao Y; Gao WM; Chen LB
World J Gastroenterol; 2008 May; 14(19):3074-80. PubMed ID: 18494062
[TBL] [Abstract][Full Text] [Related]
19. Diversity of clinical implication of B-cell translocation gene 1 expression by histopathologic and anatomic subtypes of gastric cancer.
Kanda M; Oya H; Nomoto S; Takami H; Shimizu D; Hashimoto R; Sueoka S; Kobayashi D; Tanaka C; Yamada S; Fujii T; Nakayama G; Sugimoto H; Koike M; Fujiwara M; Kodera Y
Dig Dis Sci; 2015 May; 60(5):1256-64. PubMed ID: 25487193
[TBL] [Abstract][Full Text] [Related]
20. Low expression of fibulin-1 correlates with unfavorable prognosis in gastric cancer.
Feng L; Yao C; Li P; Feng Y; Wang F; Liu YF; Guo YB; Mao QS; Xue WJ
Tumour Biol; 2016 Jul; 37(7):9399-410. PubMed ID: 26779638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
